133 related articles for article (PubMed ID: 2331447)
1. Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.
Thatcher N; Dazzi H; Mellor M; Ghosh A; Carrington B; Johnson RJ; Loriaux EM; Craig RP
Br J Cancer; 1990 Apr; 61(4):618-21. PubMed ID: 2331447
[TBL] [Abstract][Full Text] [Related]
2. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies.
O'Reilly SM; Rustin GJ; Farmer K; Burke M; Hill S; Denekamp J
Br J Cancer; 1993 Jun; 67(6):1342-5. PubMed ID: 8512818
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.
Thatcher N; Dazzi H; Johnson RJ; Russell S; Ghosh AK; Moore M; Chadwick G; Craig RD
Br J Cancer; 1989 Nov; 60(5):770-4. PubMed ID: 2803954
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.
Ghosh AK; Mellor M; Prendiville J; Thatcher N
Br J Cancer; 1990 Mar; 61(3):471-4. PubMed ID: 2328217
[TBL] [Abstract][Full Text] [Related]
5. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
[TBL] [Abstract][Full Text] [Related]
6. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites.
Stratford MR; Rustin GJ; Dennis MF; Watfa RR; Howells N; O'Reilly SM
Br J Cancer; 1993 Jun; 67(6):1351-5. PubMed ID: 8512820
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
8. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
Stoter G; Shiloni E; Aamdal S; Cleton FJ; Iacobelli S; Bijman JT; Palmer P; Franks CR; Rodenhuis S
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S41-3. PubMed ID: 2697578
[TBL] [Abstract][Full Text] [Related]
9. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.
Haworth C; O'Reilly SM; Chu E; Rustin GJ; Feldmann M
Br J Cancer; 1993 Jun; 67(6):1346-50. PubMed ID: 8512819
[TBL] [Abstract][Full Text] [Related]
10. Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production.
Thomsen LL; Baguley BC; Rustin GJ; O'Reilly SM
Br J Cancer; 1992 Oct; 66(4):723-7. PubMed ID: 1419615
[TBL] [Abstract][Full Text] [Related]
11. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma.
Flaherty LE; Redman BG; Chabot GG; Martino S; Gualdoni SM; Heilbrun LK; Valdivieso M; Bradley EC
Cancer; 1990 Jun; 65(11):2471-7. PubMed ID: 2337862
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
13. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.
Wiltrout RH; Boyd MR; Back TC; Salup RR; Arthur JA; Hornung RL
J Immunol; 1988 May; 140(9):3261-5. PubMed ID: 3258894
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
15. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
17. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.
White RL; Schwartzentruber DJ; Guleria A; MacFarlane MP; White DE; Tucker E; Rosenberg SA
Cancer; 1994 Dec; 74(12):3212-22. PubMed ID: 7982185
[TBL] [Abstract][Full Text] [Related]
18. A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma.
Lindemann A; Höffken K; Schmidt RE; Diehl V; Kloke O; Gamm H; Hayungs J; Oster W; Böhm M; Kolitz JE
Cancer Immunol Immunother; 1989; 28(4):275-81. PubMed ID: 2784715
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
[TBL] [Abstract][Full Text] [Related]
20. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.
Caligiuri MA; Murray C; Soiffer RJ; Klumpp TR; Seiden M; Cochran K; Cameron C; Ish C; Buchanan L; Perillo D
J Clin Oncol; 1991 Dec; 9(12):2110-9. PubMed ID: 1960552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
